| Objectives Parkinson’s disease insomnia is a relatively common disease in the clinic.Parkinson’s disease is the underlying disease.Insomnia is a concomitant disease.Its incidence is reported in the literature from 40% to 80%.It is mainly manifested as difficulties in falling asleep and fragmentation of sleep..A large number of studies have shown that the cause of insomnia in Parkinson’s disease may be related to the effects of the disease in patients with Parkinson’s disease,taking anti-Parkinson’s disease drugs,nocturnal symptoms,mental disorders,age and other factors,but it is not clear.At present,most drugs for treating Parkinson’s disease insomnia are drugs for treating primary insomnia,and the efficacy is often unsatisfactory.At the same time,the efficacy of sleeping drugs is related to the half-life of the drugs.This may have an unfavorable daytime effect on insomnia patients with Parkinson’s disease.Therefore,it is imperative to find an effective and less adverse drug treatment for Parkinson’s disease insomnia.Due to the limitations of western medicine treatment,Chinese medicine has a unique advantage in the treatment of insomnia caused by Parkinson’s disease through the use of a holistic concept and through dialectical treatment.A number of reports have reported that the Zishen Pingchan Decoction was created by Professor Hu Jianhua,a renowned Chinese medicine practitioner in Shanghai,and was used to treat Parkinson’s disease.In the clinical treatment of insomnia caused by Parkinson’s disease,it is found that it has a certain effect on insomnia in Parkinson’s disease.herefore,the purpose of this study was to evaluate the clinical efficacy of Zishen Pingqiao Decoction combined with right zopiclone tablets in the treatment of Parkinson’s disease insomnia(liver and kidney deficiency type).At the same time,the addition and subtraction of Zishen Pingchan Decoction in the course of clinical use The safety is evaluated.Research Methods In this study,small sample grouping controlled trials were used.The ratio between the treatment group and the control group was 1:1 for group observation.The patients were recruited from March 2016 to February 2017 in the Department of Neurology,Wuhan First Hospital.Outpatient visit to patients with Parkinson’s disease insomnia.Using a random number table method,patients were randomly divided into a treatment group and a control group,and the number of patients in both groups was 30 cases.During the experimental period,the two groups of patients continued to take anti-Parkinson’s disease drugs.During the observation period,the original drug dose was not increased as much as possible.If symptoms such as switching phenomenon or abnormality occurred,thedrugs could be adjusted appropriately.On the basis of open treatment for western medicine,the control group was given right sethoxybetaine treatment,and the treatment group Zishen Pingzheng combined with right zopiclone tablets for 12 weeks.The Pittsburgh Sleep Quality Index(PSQI)was used to evaluate the sleep status of the two groups before treatment and after the 4th and 12 th weeks of treatment.UPDRS-III was used to evaluate the exercise symptoms of the two groups.At the same time,polysomnography(PSG)was used to evaluate the sleep status of the two groups before treatment and after the 12 th week of treatment.The symptoms and signs of the patients were evaluated by using TCM syndrome graded quantitative scores.The obtained clinical data were entered into a computer and a database was established.SPSS20.0 statistical analysis software was used for statistical analysis.Count data were analyzed using X2 test.Comparisons between measurement data groups were performed for one-way analysis of variance.Comparisons within groups were first tested for normal distribution.The measurement data of the normal distribution were compared using the t-test,expressed as the mean ± standard deviation,and the non-normal distribution measurement data and clinical efficacy comparison were compared using the rank sum test.Significant differences were shown at P < 0.05.And according to the blood before and after medication,urine,liver function,renal function,ECG and other indicators comparative analysis of its safety.Research result Before the study was entered into the group,statistical methods were used to determine the age,sex,duration of Parkinson’s disease,duration of insomnia,Hoehn-Yahr grading,UPDRS-III score,total score of PSQI,PSG related indicators(sleeping time,sleep awakening.Number of times,awakening time),TCM symptom scores,etc.were not analyzed,P>0.05,the difference was not statistically significant and comparable.After 4 weeks of treatment,the total scores of the Pittsburgh Sleep Quality Index(PSQI)scores decreased in both the treatment group and the control group,and the difference between the two groups was statistically significant(P<0.05).Differences between groups were P<0.05.All were statistically significant;after 12weeks of treatment,the total score of PSQI in the two groups decreased compared with before,and the treatment group decreased significantly.The comparison within the group was P<0.05,and the difference was statistically significant;the difference betweenthe two groups was P<0.05.All have statistical significance.After 12 weeks of treatment,sleep latency,awakening frequency,and awakening time were shortened in the treatment group and the control group.The above indicators of the two groups were compared with those before treatment in each group,P<0.05,and the differences were statistically significant.Significance;Sleep latency,wakefulness,awakening time in the treatment group and the control group were compared between groups,P<0.05,the difference was statistically significant.After the 4th week of treatment,the UPDRS-III scores of the patients in the treatment group and the control group were lower than before,and the intragroup comparison was P<0.05,and the differences were statistically significant;between the groups,P<0.05,the differences were statistically significant.Significance;After 12 weeks of treatment,the UPDRS-III scores of the two groups decreased compared with before,and the treatment group decreased significantly.The comparison within the group was P<0.05,and the difference was statistically significant.The comparison between groups was P<0.05,and the differences were statistically significant.Meaning.After the 12 th week of treatment,the quantitative scores of unqualified TCM symptom scores in the treatment group and the control group decreased,and the treatment group decreased significantly.The comparison within the group was P<0.05,and the difference was statistically significant;between groups,P<0.05.The differences were statistically significant.According to the comparison of quantitative scores of TCM syndromes,after treatment,the total effective rate of insomnia in the treatment group was 93.1% in the TCM syndrome graded quantitative integrals,and the total effective rate in the control group was 82.7%.After statistical tests,the P value was < 0.05,which was statistically significant.Conclusions The use of Zishen Pingchan Decoction combined with right zopiclone tablets in the treatment of Parkinson’s disease Insomnia(liver and kidney deficiency type)and erythrocyte therapy alone can improve the patient’s sleep,such as reducing the patient’s sleep latency,sleep Awakening times,awakening time,but the movement plus nourishing kidney flattering combined with right zopiclone tablets treatment effect is more obvious.The addition of Zishenpingqiao plus orally plus szopiclone tablets was more effective than the right zosalclone tablets in the improvement of exercise symptoms,and there was no obvious clinical side effects and safety. |
PDF Full Text Request